January 2020 updates to the website
09 January 2020
The website has now been updated following January's LSCMMG/JCCCGs
The following drugs have been added/updated:
Cariprazine (Reagila ®) — Treatment of schizophrenia in adult patients
Lanreotide — Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)
Ocreotide — Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)
Cyanocobalamin — Treatment of: nutritional Vitamin B12 deficiency; vitamin B 12 deficiency following partial gastrectomy; tropical sprue, alone or with folic acid; pernicious anaemia
Azathioprine ‑ For treatment of Myasthenia Gravis
Pentosan polysulfate sodium - for treating bladder pain (NICE TA610)
Fluocinolone acetonide intravitreal implant - For treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (NICE TA613)
The following guidelines have been added/updated:
Dementia Information Sheet (Version 1.6) - Updated
Riluzole Information Sheet (Version 2.1) - Updated
The following Items will be ratified and added to the website following March’s Joint Committee of CCGs (JCCCG) Meeting:
Octreotide - Secretory gastrointestinal disorders
Lanreotide - Secretory gastrointestinal disorders
Oscillating Positive Expiratory Pressure Devices - For Non – Cystic Fibrosis Bronchiectasis
Agomelatine - For the Treatment of Major Depressive Episodes in Adults